Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2014

Toyokawa Gouji, Hirai Fumihiko, Inamasu Eiko, Yoshida Tsukihisa, Nosaki Kaname, Takenaka Tomoyoshi, Yamaguchi Masafumi, Seto Takashi, Takenoyama Mitsuhiro, Ichinose Yukito

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Bone Neoplasms
Share to Carbazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Crizotinib

Share to Gene Fusion

Share to Piperidines

Share to Pyrazoles

Source

Identifiers

PMID: 25393798
DOI: 10.1097/JTO.0000000000000358

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.PMID 25393798Read ↗

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinibSemantic proximity Read ↗

Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib.Semantic proximity Read ↗

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.Semantic proximity Read ↗

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.Semantic proximity Read ↗

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.Semantic proximity Read ↗

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.Semantic proximity Read ↗

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Semantic proximity Read ↗

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Semantic proximity Read ↗

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.